Using today’s data analysis systems, researchers conducting phenotypic screening campaigns at pharmaceutical companies processing approximately 500,000 compounds, estimate an image and data analysis time of at least three months.
Furthermore, multiple disparate software systems are used at various stages of the workflow including image analysis, cell level data analysis, well level data analysis, hit stratification, multivariate/machine learning data analysis and visualization, reporting, collaboration, and persistence.
In this webinar, PerkinElmer and AMRI will present a case study wherein High-Performance Computing (HPC) was leveraged for ultimate performance in image and data analysis of High Content Screening experiments.
Learn how to:
- Complete Batch re-analysis jobs in days
- Complete Clustering and other machine learning methods in minutes
- Balance flexibility, automation, and scalability for large and small organizations
Seungtaek Lee, Product Manager, PerkinElmer Informatics
Seungtaek Lee is the Product Manager for the TIBCO Spotfire portfolio focused on imaging and drug discovery workflows at PerkinElmer. Seungtaek came into PerkinElmer through the acquisition of Evotec Technologies in 2007 where he held various roles including application support, business development, and team leader for the High Content Screening portfolio. Prior to that, Seungtaek worked for Merck and successful started a centralized High Content Screening lab. Seungtaek holds a master’s degree in Bioengineering from University of Pennsylvania.Message Presenter
James LaRocque, Senior Research Scientist II, Lead Discovery, Albany Molecular Research Inc. (AMRI)
James LaRocque, Senior Research Scientist II, leads a team of biologists that provides state-of-the-art screening and compound characterization platforms, including high content screening and cellular imaging analysis along with traditional cellular and biochemical technologies, as part of AMRI’s integrated drug discovery center in Buffalo, NY.
Previously, LaRocque had focused on developing and implementing screening platform technologies and lead characterization initiatives to identify selective inhibitors of critical Ubiquitin pathway enzymes. LaRocque’s career of more than 20 years began in antiviral research and diversified into a wide variety of therapeutic areas while contributing to lead identification programs at both Wyeth and Pfizer. LaRocque has also led efforts in assay development, compound management, screening and hit characterization for hundreds of exploratory projects.Message Presenter
Who Should Attend?
- Director of R&D
- VP R&D
- Director of IT
- Director of R&D IT
- Screening Scientists
- Head of Department, Screening
- Director of Research IT
- Imaging Scientists
- Drug Discovery Scientists
PerkinElmer’s advanced analytics and services solutions for Clinical Development help the world’s leading biopharmaceutical, medical device and diagnostics manufactures discover new therapeutics faster by streamlining clinical operations, transforming risk into safety and enabling actionable decisions that can lead to better health outcomes.